Get started
Author

María Guirado

Observed names: Guirado, María, M. Guirado, Maria Guirado
ORCID: 0000-0001-9086-204X
Observed ORCID: 0000-0001-9086-204X
OpenAlex ID: A5064603825
SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)
2018 · M. Majem, O. Juan, et al. · Clinical & Translational Oncology · 180
Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05)
2023 · Ernest Nadal, Delvys Rodríguez-Abreu, et al. · Journal of Clinical Oncology · 125
PDF
Lung cancer symptoms at diagnosis: results of a nationwide registry study
2020 · Alberto Ruano-Raviña, Mariano Provencio, et al. · ESMO Open · 98
PDF
Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study)
2019 · Mariano Provencio, Enric Carcereny, et al. · Translational Lung Cancer Research · 86
PDF
Clinical impact of delays in the management of lung cancer patients in the last decade: systematic review
2022 · María Guirado, Elena Fernández Martín, et al. · Clinical & Translational Oncology · 59
PDF
Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non–Small Cell Lung Cancer With High Tumor Mutation Burden: A Nonrandomized Controlled Trial
2022 · Mariano Provencio, Ana Laura Ortega, et al. · JAMA Oncology · 55
PDF
Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL)
2020 · Rosario Garcia-Campelo, Oscar Arrieta, et al. · Lung Cancer · 41
Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry
2021 · Fernando Franco, Enric Carcereny, et al. · PLoS ONE · 39
PDF
Quality indicators and excellence requirements for a multidisciplinary lung cancer tumor board by the Spanish Lung Cancer Group
2021 · M. Guirado, A. Sanchez-Hernandez, et al. · Clinical & Translational Oncology · 35
PDF
Comprehensive cross‐platform comparison of methods for non‐invasive EGFR mutation testing: results of the RING observational trial
2020 · Atocha Romero, Eloisa Jantus‐Lewintre, et al. · Molecular Oncology · 28
Phase II clinical trial with metronomic oral vinorelbine and tri-weekly cisplatin as induction therapy, subsequently concomitant with radiotherapy (RT) in patients with locally advanced, unresectable, non-small cell lung cancer (NSCLC). Analysis of survival and value of ctDNA for patient selection
2021 · Mariano Provencio, Margarita Majem, et al. · Lung Cancer · 27
SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020)
2021 · E. Nadal, J. Bosch-Barrera, et al. · Clinical & Translational Oncology · 26
Sex is a strong prognostic factor in stage IV non-small-cell lung cancer patients and should be considered in survival rate estimation
2020 · Miguel Barquín, Virginia Calvo, et al. · Cancer Epidemiology · 26
OA12.05 APOLO: Phase II Trial of Induction Chemo-Immunotherapy Plus Chemoradiotherapy and Maintenance Immunotherapy in Stage III NSCLC
2024 · M. Provencio, B. Campos, et al. · Journal of Thoracic Oncology · 25
A genetic profiling guideline to support diagnosis and clinical management of lymphomas
2023 · Margarita Sánchez-Beato, Miriam Méndez, et al. · Clinical & Translational Oncology · 24
PDF
Updated analysis from the ATEZO-BRAIN trial: Atezolizumab plus carboplatin and pemetrexed in patients with advanced nonsquamous non–small cell lung cancer with untreated brain metastases.
2022 · Ernest Nadal, Delvys Rodriguez-Abreu, et al. · Journal of Clinical Oncology · 24
Induction chemo-immunotherapy followed by chemo-radiotherapy and immunotherapy maintenance in stage III NSCLC (APOLO): a phase 2 trial
2025 · Mariano Provencio, Begoña Campos, et al. · Nature Communications · 19
PDF
Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics
2022 · Mariano Provencio, Manuel Cobo, et al. · BMC Cancer · 15
Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung cancer in Spain: a nationwide cohort study
2023 · Mariano Provencio, Enric Carcereny, et al. · Translational Lung Cancer Research · 14
PDF
OA09.02 Atezo-Brain: Single Arm Phase II Study of Atezolizumab Plus Chemotherapy in Stage IV NSCLC With Untreated Brain Metastases
2021 · E. Nadal, B. Massuti, et al. · Journal of Thoracic Oncology · 14
Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A randomized phase 2 study (GOAL, Spanish Lung Cancer Group).
2018 · Rosario Garcia Campelo, Oscar Gerardo Arrieta Rodriguez, et al. · Journal of Clinical Oncology · 13
Comprehensive molecular profiling of advanced NSCLC using NGS: Prevalence of druggable mutations and clinical trial opportunities in the ATLAS study
2025 · Roberto Serna Blasco*, Pilar Mediavilla Medel*, et al. · Lung Cancer · 12
Family history of cancer and lung cancer: Utility of big data and artificial intelligence for exploring the role of genetic risk
2024 · Virginia Calvo, Emetis Niazmand, et al. · Lung Cancer · 11
PDF
Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data
2021 · Lourdes Gutiérrez, Ana Royuela, et al. · BMC Cancer · 11
PDF
Immunogenicity of COVID-19 vaccines in lung cancer patients
2023 · Mariano Provencio, Anna Estival, et al. · Lung Cancer · 9
PDF
Works count: 83
Citation count: 1,037
H-index: 17
I10-index: 24
Year
Topic
Type